{"id":"chinese-patent-medicine","safety":{"commonSideEffects":[]},"_chembl":null,"_fixedAt":"2026-03-30T13:57:48.273102","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Chinese patent medicines typically contain combinations of herbs, minerals, and animal-derived ingredients that work synergistically according to traditional Chinese medicine theory. Without specification of the exact formulation, the mechanism likely involves anti-inflammatory, immunomodulatory, or qi/blood-tonifying effects. The specific molecular targets and pathways depend on the individual herbal components and their active compounds.","oneSentence":"A traditional Chinese patent medicine formulation that modulates multiple biological pathways to address disease through herbal and mineral constituents.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:05:40.096Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"_fixedFields":["pubmed(1088)"],"trialDetails":[{"nctId":"NCT07455240","phase":"PHASE1","title":"A Study to Learn About How the Body Processes the Study Medicine Called PF-07328948 in Healthy Chinese Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2026-03-02","conditions":"Healthy Participant","enrollment":10},{"nctId":"NCT06666413","phase":"PHASE4","title":"China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPD","status":"RECRUITING","sponsor":"Genzyme, a Sanofi Company","startDate":"2025-05-07","conditions":"Glycogen Storage Disease Type II, Pompe's Disease","enrollment":13},{"nctId":"NCT06983665","phase":"NA","title":"Human Bioequivalence Study of Liposomal Amphotericin B for Injection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sichuan Huiyu Pharmaceutical Co., Ltd","startDate":"2025-05-25","conditions":"Invasive Fungal Infections, Neutropenic Fever, Visceral Leishmaniasis","enrollment":42},{"nctId":"NCT07485543","phase":"EARLY_PHASE1","title":"Safety and Efficacy of Inhaled BMD003 (CFTR mRNA) in Chinese Cystic Fibrosis Patients Aged ≥12 Years","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2026-03","conditions":"Cystic Fibrosis","enrollment":24},{"nctId":"NCT06994897","phase":"PHASE1","title":"A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body of Healthy Adults","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-08-13","conditions":"Healthy","enrollment":92},{"nctId":"NCT07235163","phase":"PHASE1","title":"A Study to Learn How Different Amounts of the Study Medicine Called PF-08065010 Are Tolerated and Act in the Body of Healthy Adults","status":"NOT_YET_RECRUITING","sponsor":"Pfizer","startDate":"2026-04-13","conditions":"Healthy","enrollment":100},{"nctId":"NCT07235150","phase":"PHASE1","title":"A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body in Healthy Adults","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-12-11","conditions":"Healthy","enrollment":76},{"nctId":"NCT07476963","phase":"PHASE1","title":"Evaluation of the Food Effecton the Pharmacokinetics of FWD1802 in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Forward Pharmaceuticals Co., Ltd.","startDate":"2026-03","conditions":"Healthy","enrollment":18},{"nctId":"NCT03523442","phase":"PHASE1","title":"A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-08-31","conditions":"Prostatic Neoplasms","enrollment":19},{"nctId":"NCT07052110","phase":"NA","title":"DST in Reducing Depressive Symptoms, Enhancing Self-esteem, and Promoting Quality of Life Among CCSs","status":"RECRUITING","sponsor":"The Hong Kong Polytechnic University","startDate":"2023-10-16","conditions":"Cancer","enrollment":248},{"nctId":"NCT05460273","phase":"PHASE1, PHASE2","title":"A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2022-07-11","conditions":"Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Cancer","enrollment":119},{"nctId":"NCT07220538","phase":"PHASE4","title":"A Study Testing How Well the Drug Extract of Ginkgo Biloba Leaves Tablets Works for People With Memory or Thinking Problems After a Stroke When Added to Standard Treatment","status":"RECRUITING","sponsor":"Dr. Willmar Schwabe GmbH & Co. KG","startDate":"2025-11-28","conditions":"Ischemic Stroke Hospitalized, Impairment, Cognitive","enrollment":400},{"nctId":"NCT05902598","phase":"PHASE3","title":"A Phase 3 Study of ARO-APOC3 / VSA001 / SAR449124 (Plozasiran) in Chinese Adults With Familial Chylomicronemia Syndrome","status":"COMPLETED","sponsor":"Visirna Therapeutics HK Limited","startDate":"2023-07-10","conditions":"Familial Chylomicronemia Syndrome","enrollment":37},{"nctId":"NCT04945720","phase":"PHASE2","title":"Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2022-04-11","conditions":"Hepatocellular Carcinoma","enrollment":30},{"nctId":"NCT07339267","phase":"PHASE1","title":"A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2026-01-20","conditions":"Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer","enrollment":12},{"nctId":"NCT07331194","phase":"PHASE1","title":"Pharmacokinetics and Bioequivalence Study of HMPL-523 Acetate Tablets in Humans","status":"COMPLETED","sponsor":"Hutchmed","startDate":"2025-10-28","conditions":"Healthy","enrollment":54},{"nctId":"NCT07390565","phase":"NA","title":"YSQTG Combined With Immuno-chemotherapy for Extensive-Stage Small Cell Lung Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"LI FENG","startDate":"2026-02-17","conditions":"Extensive-stage Small Cell Lung Cancer (SCLC)","enrollment":308},{"nctId":"NCT04076059","phase":"PHASE3","title":"An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma China, Inc.","startDate":"2019-09-11","conditions":"Metastatic Hormone Sensitive Prostate Cancer","enrollment":180},{"nctId":"NCT07384104","phase":"PHASE1","title":"Compare the Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of SAL023 and Italy-Manufactured Evenity in Healthy Subjects","status":"ENROLLING_BY_INVITATION","sponsor":"Shenzhen Salubris Pharmaceuticals Co., Ltd.","startDate":"2025-10-19","conditions":"Osteoporosis","enrollment":118},{"nctId":"NCT04590235","phase":"PHASE1","title":"A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-12-16","conditions":"Neurofibromatosis 1, Neurofibroma Plexiform","enrollment":32},{"nctId":"NCT06091267","phase":"PHASE1, PHASE2","title":"PK/Efficacy Bridging Study of ASTX727 in Chinese Subjects With Myelodysplastic Syndromes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Otsuka Beijing Research Institute","startDate":"2023-10-16","conditions":"Myelodysplastic Syndromes","enrollment":72},{"nctId":"NCT06930157","phase":"PHASE4","title":"Multi-center Randomized Controlled Clinical Study of Shenling Baishu Granule to Prevent the Recurrence of Low-risk Colorectal Adenoma","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2025-11-24","conditions":"Low-risk Colorectal Adenoma","enrollment":624},{"nctId":"NCT07357610","phase":"PHASE1","title":"An Open-Label Drug Interaction Clinical Study to Evaluate Itraconazole, Rifampin, Midazolam and SIM0270 in Chinese Healthy Adult Participants","status":"RECRUITING","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2026-01-05","conditions":"Healthy Adult Participants","enrollment":60},{"nctId":"NCT07357324","phase":"PHASE4","title":"A Clinical Observation Study of a Chinese Patent Medicine Combined With Tamsulosin in Improving Sleep and Nocturia Symptoms After Enucleation of the Prostate","status":"RECRUITING","sponsor":"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","startDate":"2024-12-01","conditions":"Benign Prostatic Hyperplasia, Nocturia Associated With Nocturnal Polyuria","enrollment":136},{"nctId":"NCT07340177","phase":"PHASE4","title":"Xiaojin Pill/Neixiao Luoli Pill for the Treatment of Thyroid Nodules","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang Provincial People's Hospital","startDate":"2026-03","conditions":"Thyroid Nodules","enrollment":108},{"nctId":"NCT07292038","phase":"PHASE1","title":"Safety and Pharmacokinetics of NM6603 in Chinese Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"NucMito Pharmaceuticals Co. Ltd.","startDate":"2025-12-18","conditions":"Cancers","enrollment":30},{"nctId":"NCT06883110","phase":"NA","title":"Angong Niuhuang Pills With Different Bovine Bezoar Formulation Sources in the Treatment of AIS","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-09-01","conditions":"Acute Ischemic Stroke","enrollment":100},{"nctId":"NCT06806046","phase":"PHASE1","title":"Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2024-12-20","conditions":"Solid Tumors, Colorectal Cancer","enrollment":12},{"nctId":"NCT07331389","phase":"PHASE1","title":"A Drug-Drug Interaction Study of HDM1002 and Metformin, Empagliflozin, Midazolam, Valsartan, and Warfarin","status":"RECRUITING","sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","startDate":"2025-09-24","conditions":"Overweight Subject, Healthy Subjects","enrollment":111},{"nctId":"NCT07330648","phase":"PHASE2","title":"Prospective Clinical Trial of Crisugabalin Capsules in the Treatment of Generalized Anxiety Disorder","status":"RECRUITING","sponsor":"Anhui Medical University","startDate":"2025-10-10","conditions":"Generalized Anxiety Disorder","enrollment":216},{"nctId":"NCT05013190","phase":"","title":"A Study of NINLARO® in Chinese Adults With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2021-10-29","conditions":"Multiple Myeloma","enrollment":72},{"nctId":"NCT05228470","phase":"PHASE2","title":"A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-12-21","conditions":"Elranatamab, Myeloma, Multiple Myeloma","enrollment":39},{"nctId":"NCT07077434","phase":"PHASE1","title":"A Study to Assess Safety, Tolerability and Drug Levels of BMS-986504 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-10-15","conditions":"Advanced Solid Tumors","enrollment":32},{"nctId":"NCT05704049","phase":"PHASE2","title":"A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2023-04-05","conditions":"Relapsed/Refractory Multiple Myeloma","enrollment":118},{"nctId":"NCT05834868","phase":"PHASE3","title":"Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Tonghua Dongbao Pharmaceutical Co.,Ltd","startDate":"2022-05-06","conditions":"Type 2 Diabetes","enrollment":1040},{"nctId":"NCT05845645","phase":"PHASE1","title":"A Study to Test Bioavailability of of 2 New Formulations of UCB0599 in Healthy Participants in Part A and to Test Safety, Tolerability, and Pharmacokinetic (PK) of UCB0599 in Healthy Japanese and Chinese Participants in Part B","status":"COMPLETED","sponsor":"UCB Biopharma SRL","startDate":"2023-05-31","conditions":"Healthy Study Participants","enrollment":73},{"nctId":"NCT07295873","phase":"PHASE1","title":"Drug-Drug Interaction Study Between Hydronidone and Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide, and Tenofovir Amibufenamide","status":"NOT_YET_RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2025-12-30","conditions":"Chronic Hepatitis B Liver Fibrosis, DDI (Drug-Drug Interaction)","enrollment":64},{"nctId":"NCT06768619","phase":"NA","title":"Bioequivalence Study of Eltrombopag Olamine Tablets in Healthy Subjects in the Fed State","status":"COMPLETED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2023-03-20","conditions":"Thrombocytopenia","enrollment":36},{"nctId":"NCT07284173","phase":"PHASE1","title":"A Study to Learn if a Medicine That Reduces Stomach Acid Affects the Blood Level of Study Medicine PF-08049820 in Healthy Chinese Adults.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2025-11-03","conditions":"Healthy Adults","enrollment":18},{"nctId":"NCT06549816","phase":"PHASE1","title":"A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2024-08-21","conditions":"Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma","enrollment":6},{"nctId":"NCT07268430","phase":"NA","title":"Bioequivalence Study of Long-Acting Paliperidone Palmitate in Patients With Schizophrenia","status":"COMPLETED","sponsor":"CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.","startDate":"2023-12-18","conditions":"Schizophrenia","enrollment":256},{"nctId":"NCT07183345","phase":"EARLY_PHASE1","title":"Application of Dynamic Pain Assessment and Management System in Perioperative Period of Patients With Incarcerated Mixed Hemorrhoids","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Hospital of Putian University","startDate":"2025-12-01","conditions":"Incarcerated Mixed Hemorrhoids","enrollment":64},{"nctId":"NCT05458011","phase":"PHASE3","title":"A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults With Migraine","status":"COMPLETED","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","startDate":"2022-09-30","conditions":"Migraine","enrollment":365},{"nctId":"NCT06749236","phase":"PHASE1","title":"A Study to Evaluate the Bioavailability of Two Specifications of Oral Deuremidevir Hydrobromide for Suspension","status":"COMPLETED","sponsor":"Vigonvita Life Sciences","startDate":"2025-08-11","conditions":"Healthy Participants","enrollment":18},{"nctId":"NCT06954155","phase":"PHASE3","title":"Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events-BEYOND","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2025-05-30","conditions":"Stroke","enrollment":330},{"nctId":"NCT07030595","phase":"PHASE3","title":"AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia","status":"COMPLETED","sponsor":"Alebund Pharmaceuticals","startDate":"2023-06-12","conditions":"ESRD (End Stage Renal Disease), Chronic Kidney Disease(CKD), Hyperphosphatemia","enrollment":474},{"nctId":"NCT06327815","phase":"PHASE4","title":"Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-03-15","conditions":"Type 2 Diabetes Mellitus (T2DM)","enrollment":633},{"nctId":"NCT07200362","phase":"","title":"Study of Compound Nanxing Zhitong Ointment in the Treatment of Chronic Pain in Musculoskeletal System","status":"COMPLETED","sponsor":"Jiangsu Kanion Pharmaceutical Co., Ltd","startDate":"2021-10-30","conditions":"Chronic Primary Musculoskeletal Pain","enrollment":3029},{"nctId":"NCT06712082","phase":"PHASE1","title":"A Study to Learn More About the Study Medicine PF-07264660 in Healthy Chinese Adult Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2025-02-24","conditions":"Healthy","enrollment":12},{"nctId":"NCT05413369","phase":"PHASE3","title":"iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-07-07","conditions":"Type 2 Diabetes Mellitus","enrollment":582},{"nctId":"NCT03992469","phase":"PHASE1","title":"Study to Evaluate Safety, Tolerability and Efficacy of Oral E-B-FAHF-2 in Mild-to-Moderate Crohn's Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2023-02-15","conditions":"Crohn's Disease","enrollment":7},{"nctId":"NCT05442554","phase":"PHASE4","title":"A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma","status":"COMPLETED","sponsor":"Takeda","startDate":"2022-11-28","conditions":"T-Cell Lymphoma","enrollment":10},{"nctId":"NCT07181265","phase":"PHASE1","title":"Drug-Drug Interaction of JMKX003142 With Amiodarone and Febuxostat in Healthy Subjects","status":"NOT_YET_RECRUITING","sponsor":"Jemincare","startDate":"2025-10-30","conditions":"Autosomal Dominant Polycystic Kidney Disease (ADPKD)","enrollment":48},{"nctId":"NCT06942234","phase":"PHASE1, PHASE2","title":"Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer","status":"RECRUITING","sponsor":"Jiangsu Alphamab Biopharmaceuticals Co., Ltd","startDate":"2025-06-01","conditions":"Inoperable Locally Advanced HER2-Negative Breast Cancer, Metastatic HER2-Negative Breast Cancer","enrollment":180},{"nctId":"NCT04656600","phase":"PHASE4","title":"Study to Evaluate Efficacy and Safety of Imiglucerase Treatment in Chinese Patients With Gaucher Disease Type Ⅲ","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-03-02","conditions":"Gaucher's Disease","enrollment":12},{"nctId":"NCT07170254","phase":"NA","title":"A Clinical Study on the Evaluation of BD114 for the Treatment HPV-16-Related Cervical HSIL","status":"RECRUITING","sponsor":"Shanghai BDgene Co., Ltd.","startDate":"2025-09","conditions":"High-grade Squamous Intraepithelial Lesions (HSIL)","enrollment":12},{"nctId":"NCT07162116","phase":"PHASE1","title":"A Study to Evaluate the Effect of XY0206 on the QTc Interval in Chinese Healthy Participants","status":"RECRUITING","sponsor":"Shijiazhuang Yiling Pharmaceutical Co. Ltd","startDate":"2025-07-06","conditions":"Acute Myeloid Leukemia With FLT3/ITD Mutation","enrollment":45},{"nctId":"NCT06675188","phase":"PHASE1","title":"A Study to Learn More About the Study Medicine PF-07275315 in Healthy Chinese Adult Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2025-01-06","conditions":"Healthy","enrollment":13},{"nctId":"NCT04644575","phase":"PHASE3","title":"Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bioverativ, a Sanofi company","startDate":"2021-02-23","conditions":"Hemophilia A","enrollment":261},{"nctId":"NCT06671873","phase":"PHASE1","title":"Study on Mass Balance of [14C]HMPL-306（Isocitrate Dehydrogenase Inhibitor） in Healthy Chinese Adult Male Subjects","status":"COMPLETED","sponsor":"Hutchmed","startDate":"2024-11-26","conditions":"Mass Balance Study","enrollment":6},{"nctId":"NCT05673785","phase":"PHASE2","title":"A Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in Chinese Participants With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Takeda","startDate":"2023-02-10","conditions":"Lymphoma","enrollment":52},{"nctId":"NCT07057609","phase":"PHASE1","title":"Bioequivalence Study of Propofol Medium and Long Chain Fat Emulsion Injection in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"Haisco Pharmaceutical Group Co., Ltd.","startDate":"2018-10-16","conditions":"Healthy","enrollment":36},{"nctId":"NCT06973304","phase":"PHASE3","title":"A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-06-26","conditions":"Short Bowel Syndrome","enrollment":13},{"nctId":"NCT07054255","phase":"PHASE1","title":"Bioequivalence Study of Ranolazine Extended-release Tablets in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"Haisco Pharmaceutical Group Co., Ltd.","startDate":"2020-09-06","conditions":"Healthy","enrollment":72},{"nctId":"NCT06491550","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-07-15","conditions":"Healthy Participants","enrollment":91},{"nctId":"NCT04193371","phase":"NA","title":"Effects of Acupuncture on Body Mass Index in Overweight and Obese Women With Polycystic Ovary Syndrome (PCOS )","status":"COMPLETED","sponsor":"Peking University Third Hospital","startDate":"2019-12-06","conditions":"PCOS, Overweight, Obesity","enrollment":106},{"nctId":"NCT06616415","phase":"PHASE4","title":"A Clinical Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Belumosudil in Chinese Adolescents With cGVHD Who Have Had an Inadequate Response to Glucocorticoids or Other Systemic Therapies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2024-12-04","conditions":"Chronic Graft Versus Host Disease","enrollment":6},{"nctId":"NCT07032116","phase":"","title":"YiqiJiangzhuoHuoxueTongluo Method to Delay the Occurrence of End-stage Renal Disease in Diabetic Kidney Disease--Study1","status":"NOT_YET_RECRUITING","sponsor":"Liu Hongfang","startDate":"2025-08-01","conditions":"Diabetic Kidney Disease (DKD)","enrollment":4472},{"nctId":"NCT05171387","phase":"PHASE2","title":"Darolutamide + Androgen Deprivation Therapy (ADT) in Chinese Men With High Risk, Nonmetastatic Prostate Cancer","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-11-30","conditions":"Prostate Cancer","enrollment":78},{"nctId":"NCT06985680","phase":"NA","title":"Diabetic Patients,Self-Efficacy,Self-Care Behaviors,Artificial Intelligence-Based","status":"COMPLETED","sponsor":"Chia-Tzu Line","startDate":"2024-02-01","conditions":"Diabetic Patients,Self-Care,Artificial Intelligence-Based,Self-Efficacy, Type 2 Diabetes Mellitus (T2DM)","enrollment":104},{"nctId":"NCT06900543","phase":"PHASE3","title":"Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere","status":"RECRUITING","sponsor":"Chengdu New Radiomedicine Technology Co. LTD.","startDate":"2025-04-15","conditions":"Unresectable Hepatocellular Carcinoma","enrollment":108},{"nctId":"NCT05955391","phase":"PHASE2","title":"TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shenzhen TargetRx Co., Ltd.","startDate":"2023-01-18","conditions":"Non-small Cell Lung Cancer","enrollment":164},{"nctId":"NCT06082635","phase":"PHASE3","title":"TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shenzhen TargetRx Co., Ltd.","startDate":"2023-12-14","conditions":"Non Small Cell Lung Cancer","enrollment":321},{"nctId":"NCT06304805","phase":"PHASE1","title":"TGRX-326 Pharmacokinetic Food Effect Bioavailability Study","status":"COMPLETED","sponsor":"Shenzhen TargetRx Co., Ltd.","startDate":"2023-12-13","conditions":"Non Small Cell Lung Cancer","enrollment":24},{"nctId":"NCT06946095","phase":"PHASE3","title":"Efficacy and Safety of Xinyue Capsule in the Treatment of Heart Failure With Preserved Ejection Fraction","status":"NOT_YET_RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2025-05-20","conditions":"Heart Failure","enrollment":246},{"nctId":"NCT05130788","phase":"NA","title":"WeChat Quit Coach Pilot Study","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2022-02-10","conditions":"Smoking Cessation","enrollment":150},{"nctId":"NCT06890715","phase":"PHASE1","title":"Comparative Pharmacokinetic Study of Ramelteon Modified-Release Tablets and Ramelteon Tablets in Healthy Subjects","status":"COMPLETED","sponsor":"Overseas Pharmaceuticals, Ltd.","startDate":"2024-06-24","conditions":"Chronic Insomnia Characterized","enrollment":12},{"nctId":"NCT04177823","phase":"PHASE1","title":"A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-12-09","conditions":"Multiple Myeloma","enrollment":6},{"nctId":"NCT06569381","phase":"PHASE1","title":"Comparative Pharmacokinetic Study of Pirfenidone Modified-Release Tablets in Healthy Subjects Under Fasting and Fed Conditions","status":"COMPLETED","sponsor":"Overseas Pharmaceuticals, Ltd.","startDate":"2024-09-18","conditions":"Idiopathic Pulmonary Fibrosis","enrollment":18},{"nctId":"NCT06678542","phase":"PHASE1","title":"Study to Assess Relative Bioavailability of GP681 Formulations in Healthy Chinese Male Subjects","status":"COMPLETED","sponsor":"Jiangxi Qingfeng Pharmaceutical Co. Ltd.","startDate":"2024-09-27","conditions":"Healthy Participants","enrollment":36},{"nctId":"NCT06863831","phase":"NA","title":"A Multicenter Trial of YSQTG vs. Simulated Agents With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy for EC","status":"ENROLLING_BY_INVITATION","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-08-22","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":536},{"nctId":"NCT06857799","phase":"PHASE1","title":"A Study on the Safety, Tolerability and Pharmacokinetics of WS-0101 Tablets in Chinese Healthy Subjects","status":"COMPLETED","sponsor":"Peking University First Hospital","startDate":"2024-05-13","conditions":"Healthy Adult Subjects","enrollment":27},{"nctId":"NCT06837597","phase":"PHASE3","title":"Jianzhong Qushi in Chronic RRI","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-03-15","conditions":"Chronic Radiation Proctitis","enrollment":168},{"nctId":"NCT05434312","phase":"PHASE1","title":"TGRX-678 Chinese Phase I in Chronic Myelogenous Leukemia (CML) Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shenzhen TargetRx Co., Ltd.","startDate":"2021-03-29","conditions":"Chronic Myelogenous Leukemia","enrollment":90},{"nctId":"NCT05987072","phase":"PHASE1","title":"A Study to Learn How the Study Medicine Called Sisunatovir is Tolerated and Acts in the Bodies of Chinese Healthy Adults.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-11-03","conditions":"Respiratory Syncytial Virus Infection","enrollment":12},{"nctId":"NCT02972372","phase":"NA","title":"Chemoradiation Versus Esophagectomy for Locally Advanced Esophageal Cancer","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Henan University of Science and Technology","startDate":"2016-11","conditions":"Esophagus Cancer","enrollment":196},{"nctId":"NCT04676373","phase":"PHASE4","title":"Study to Evaluate Efficacy and Safety in Chinese Patients With Late Onset Pompe Disease With Alglucosidase Alfa Treatmen","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2021-03-10","conditions":"Pompe's Disease","enrollment":41},{"nctId":"NCT05732428","phase":"PHASE1","title":"A Study to Learn About the Study Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Advanced Breast Cancer in China","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-02-20","conditions":"Breast Cancer","enrollment":9},{"nctId":"NCT05759754","phase":"NA","title":"Effects of Traditional Chinese Medicine (GSJYF) in Children With Inherited Proteinuric Kidney Disease","status":"COMPLETED","sponsor":"Children's Hospital of Fudan University","startDate":"2023-09-17","conditions":"Proteinuria, Kidney Diseases, Hereditary Nephropathy","enrollment":72},{"nctId":"NCT05960032","phase":"PHASE1","title":"A Study to Learn About the Study Medicine Called Zavegepant in Healthy Chinese Adult Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-10-23","conditions":"Healthy","enrollment":13},{"nctId":"NCT06220019","phase":"","title":"REspiratory diSEAse cohoRt Studies of CHinese Medicine for Pneumonia (RESEARCH-Pneumonia)","status":"NOT_YET_RECRUITING","sponsor":"Henan University of Traditional Chinese Medicine","startDate":"2024-12-26","conditions":"Pneumonia","enrollment":5000},{"nctId":"NCT06750419","phase":"PHASE3","title":"89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study","status":"RECRUITING","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","startDate":"2024-11-06","conditions":"Clear Cell Renal Cell Carcinoma","enrollment":82},{"nctId":"NCT04910256","phase":"PHASE4","title":"Clinical Study on Huatuo Zaizao Pills for Post-stroke Treatment","status":"COMPLETED","sponsor":"Xiyuan Hospital of China Academy of Chinese Medical Sciences","startDate":"2021-05-31","conditions":"Ischemic Stroke","enrollment":80},{"nctId":"NCT04449861","phase":"PHASE3","title":"Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-12-07","conditions":"Small Cell Lung Carcinoma Extensive Disease","enrollment":166},{"nctId":"NCT06527755","phase":"PHASE1","title":"A Study to Assess the PK, PD, Safety and Tolerability of Eplontersen in Healthy Chinese Volunteers","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-08-06","conditions":"Transthyretin-mediated Amyloidosis","enrollment":12},{"nctId":"NCT05896774","phase":"PHASE1","title":"A Study to Learn About the Study Medicine (Maplirpacept) in People With Advanced Non-Hodgkin Lymphoma or Multiple Myeloma in China","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-06-28","conditions":"Non-Hodgkin Lymphoma, Multiple Myeloma","enrollment":10},{"nctId":"NCT02261532","phase":"PHASE1","title":"A Phase I Study of TAS-102 in Solid Tumors","status":"COMPLETED","sponsor":"Taiho Pharmaceutical Co., Ltd.","startDate":"2014-09","conditions":"Advanced or Metastatic Solid Tumors","enrollment":15},{"nctId":"NCT05711797","phase":"PHASE1","title":"Pharmacokinetic Characteristics of Subjects with Hepatic Insufficiency and Healthy Subjects","status":"COMPLETED","sponsor":"Nanjing Zenshine Pharmaceuticals","startDate":"2023-04-12","conditions":"Influenza, Human","enrollment":16},{"nctId":"NCT04882085","phase":"PHASE4","title":"Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-08-26","conditions":"Urinary Tract Infection, Acute Pyelonephritis, Hospital Acquired Pneumonia","enrollment":60},{"nctId":"NCT03710915","phase":"PHASE1","title":"A Study of HG146 Capsule in Chinese Subjects with Relapsed and Refractory Multiple Myeloma","status":"TERMINATED","sponsor":"HitGen Inc.","startDate":"2019-01-12","conditions":"Multiple Myeloma, Relapsed and Refractory Multiple Myeloma","enrollment":3}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1088,"recentPublications":[{"date":"2026","pmid":"41884091","title":"Anshen Bunao syrup as a potential anti-aging agent: mechanistic insights and pharmacological evidence.","journal":"Frontiers in aging"},{"date":"2026 Mar 5","pmid":"41830714","title":"E-nose, HS-SPME-GC-MS and untargeted metabolomics reveal effects on (60)Co gamma irradiation of Neng-An-Jun-Ning Pills: Changes in odor and chemical compositions.","journal":"Journal of pharmaceutical and biomedical analysis"},{"date":"2026 Feb","pmid":"41814840","title":"[Safety grading of Chinese patent medicines (including injections) during pregnancy].","journal":"Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica"},{"date":"2026 Feb","pmid":"41814809","title":"[Evidence mapping of clinical research on Chinese patent medicines for treating lung cancer in recent five years].","journal":"Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica"},{"date":"2026 Jan","pmid":"41814744","title":"[Analysis of clinical research evidence diagrams on intervention of vascular dementia with oral Chinese patent medicines].","journal":"Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Chinese patent medicine","genericName":"Chinese patent medicine","companyName":"Tianjin University of Traditional Chinese Medicine","companyId":"tianjin-university-of-traditional-chinese-medicine","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}